Skip to main content

Clinical Trials Using Tacrolimus

Review the clinical trials studying tacrolimus on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 41

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Status: Active
Location: 18 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 20 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 10 locations
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Status: Active
Location: 6 locations
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Status: Active
Location: 6 locations
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Location: 4 locations
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Status: Active
Location: 5 locations
Orca Q Stem Cells for the Treatment of Pediatric Patients with Leukemia
Status: Active
Location: 4 locations
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients with Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 3 locations
T Cells (EAGD T-Cells) after Stem Cell Transplantation and Post-transplant Cyclophosphamide for the Treatment of Blood Cancers
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Reduced Intensity or Nonmyeloablative Conditioning With Orca-T for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Total Marrow and Lymphoid Irradiation as Conditioning Regimen before Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome or Acute Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Status: Active
Location: Boston Children's Hospital, Boston, Massachusetts
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Peritransplant Ruxolitinib for Patients with Primary and Secondary Myelofibrosis
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Total Marrow and Lymphoid Irradiation before Donor Transplant and Cyclophosphamide in Treating patients with Acute Myeloid Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Ruxolitinib and Donor Stem Cell Transplant for the Treatment of Myelofibrosis Patients with Splenomegaly
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Status: Active
Location: Yale University, New Haven, Connecticut